Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company.

The upfront cash payment of $4.10 per share of common stock represents a premium of around 66% to Checkpoint’s closing share ...

Sun Pharma to acquire Checkpoint Therapeutics, expanding innovative portfolio in onco-derm therapy with FDA-approved UNLOXCYT ...

Sun Pharmaceuticals announced that it will acquire Checkpoint Therapeutics, a company specializing in immunotherapy and ...

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its ...

Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...

Sun Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...